Erdafitinib for the treatment of urothelial cancer

Area of Science:

• Oncology
• Pharmacology
• Precision Medicine

Background:

• Fibroblast growth-factor receptor (FGFR) inhibition is an emerging treatment strategy for urothelial cancer (UC).
• FGFR3 mutations or fusions are prevalent in the luminal-1 UC subtype, which is often resistant to immunotherapy.
• Erdafitinib, a pan-FGFR tyrosine kinase inhibitor, has demonstrated significant efficacy in preclinical and clinical studies.

Purpose of the Study:

• To review the preclinical and clinical evidence supporting erdafitinib in urothelial cancer treatment.
• To summarize the outcomes of other FGFR inhibitors investigated in UC.
• To explore future directions for FGFR inhibition in the therapeutic landscape of UC.

Main Methods:

• Review of preclinical data and clinical trial results, including the phase 2 BLC2001 trial (NCT02365597).
• Analysis of erdafitinib's efficacy and safety profile in metastatic UC with specific genetic alterations.
• Synthesis of information on other FGFR inhibitors and future therapeutic strategies.

Main Results:

• Erdafitinib demonstrated an overall response rate of 40% in metastatic UC patients with FGFR3 mutations or fusions.
• Erdafitinib is the first targeted therapy approved for metastatic UC harboring FGFR3 alterations.
• FGFR inhibitors have shown promise, but typical class-related adverse effects require careful management.

Conclusions:

• The approval of erdafitinib represents a significant advancement in precision medicine for UC.
• Erdafitinib serves as a crucial comparator for salvage therapy in UC.
• Future research should focus on optimizing diagnostic tools, exploring liquid biopsies, and evaluating combinations with immunotherapy.